Wedbush raised the firm’s price target on TScan Therapeutics (TCRX) to $5 from $4 and keeps an Outperform rating on the shares. The firm says the company reported earnings and plans to present initial results from Cohort C from its Phase 1 ALLOHA trial in Q2, with an update planned in the second half of 2026. In Wedbush’s view, EHA and ASH would be likely respective platforms.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TCRX:
- TScan Therapeutics: Strengthening Heme-Focused TCR-T Platform and Regulatory Momentum Support Buy Rating and $7 Target
- TScan Therapeutics reports Q4 EPS (18c), consensus (28c)
- TScan Therapeutics sees cash runway into 2H27
- TScan Therapeutics: Clinical Momentum in TSC-101 and Pipeline Expansion Underpin Buy Rating Despite Cash Constraints
- TScan Therapeutics completes enrollment into Cohort C of ALLOHA study